Sorintellis

Sorintellis is a Montreal-based life sciences technology company on a mission to transform the clinical drug development process through the power of artificial intelligence. Our proprietary platform streamlines trial design and operations, delivering actionable insights that enable faster, more precise, and informed decision-making. Sorintellis’ AI-powered decision-support platform assesses the success probability of drug development programs, enabling pharmaceutical companies, CROs, biotech firms, and life sciences investors to mitigate R&D and trial-related risks, optimize trial design, prioritize pipeline assets, and make informed portfolio decisions. At Sorintellis, we understand that the challenges of drug development delays, failures, and rising costs are not only rooted in clinical efficacy or safety issues, but also stem from a complex interplay of operational, strategic, regulatory, commercial, and financial risks. Our platform is designed to address these multidimensional challenges holistically. Our powerful approach is strategically built on Sorintellis’ proprietary large-scale multimodal database expertly curated, manually annotated, and rigorously validated by pharmaceutical experts in clinical trials, regulatory affairs, biostatistics, market access, pharmacology, drug safety, pricing strategy, portfolio management, and life sciences investment ensuring exceptional data quality and contextual relevance across the entire drug development lifecycle. Our vision is clear: to revolutionize clinical trials and pharmaceutical portfolio management through AI-powered decision support systems that enhance strategic planning and drive successful clinical execution. We empower life sciences stakeholders to deliver impactful therapies faster by enabling smarter, more confident decisions that enhance both clinical and commercial value. Join us in reshaping the future of drug development. https://sorintellisgroup.com/contact-us/ or contact@sorintellis.ai